ACM
KALA icon

Athyrium Capital Management’s KALA BIO KALA Stock Holding History

Athyrium Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$5.07M Hold
534
– – 100% 1
2019
Q2 		$8.51M Hold
534
– – 100% 1
2019
Q1 		$11M Hold
534
– – 11.27% 2
2018
Q4 		$6.52M Buy
+534
New +$9.26M 6.28% 3

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Athyrium Capital Management's KALA Position: Q3 2019 in Review

Athyrium Capital Management held its KALA BIO (KALA) position steady in Q3 2019 at 534 shares worth $5.07M. The position accounts for 100% of the portfolio, ranked #1.

Athyrium Capital Management first reported a position in KALA in Q4 2018 and has held it in 4 quarters since. The position peaked at $11M in Q1 2019. 64 funds tracked by Wall St. Rank hold KALA as of Q3 2019.

  • Athyrium Capital Management held 534 shares of KALA BIO worth $5.07M as of Q3 2019.
  • Athyrium Capital Management left its KALA BIO share count unchanged in Q3 2019.
  • KALA BIO made up 100% of Athyrium Capital Management's portfolio in Q3 2019, its #1 holding.
  • Athyrium Capital Management first reported a position in KALA BIO in Q4 2018 and has held it in 4 quarters since.
  • Athyrium Capital Management's KALA BIO position peaked at $11M in Q1 2019.
  • 64 funds tracked by Wall St. Rank held KALA BIO as of Q3 2019.

Based on Athyrium Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.